Literature DB >> 24861329

Prostate cancer: primary ADT monotherapy not suitable for localized disease.

Oliver Sartor1, Jonathan Silberstein1.   

Abstract

Although current guidelines do not endorse the use of primary androgen deprivation therapy (PADT) as monotherapy for localized prostate cancer, many patients continue to receive this treatment. New outcomes research confirms that there is no clear reason for use of PADT in men with localized prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24861329     DOI： 10.1038/nrurol.2014.119

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  7 in total

1.  Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Authors:  Arnold L Potosky; Reina Haque; Andrea E Cassidy-Bushrow; Marianne Ulcickas Yood; Miao Jiang; Huei-Ting Tsai; George Luta; Nancy L Keating; Matthew R Smith; Stephen K Van Den Eeden
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

2.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

3.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

Review 4.  Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Authors:  Lockwood G Taylor; Steven E Canfield; Xianglin L Du
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

5.  Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.

Authors:  Ofer Yossepowitch; Scott E Eggener; Fernando J Bianco; Brett S Carver; Angel Serio; Peter T Scardino; James A Eastham
Journal:  J Urol       Date:  2007-06-11       Impact factor: 7.450

6.  Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients.

Authors:  Jinan Liu; Lizheng Shi; Oliver Sartor; Richard Culbertson
Journal:  Onco Targets Ther       Date:  2013-06-17       Impact factor: 4.147

7.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.